J.P. Morgan Disclosures5-15-14

J.P.Morgan's Geoff Meacham Plucks Biotechs with Upside from a Down Market

J.P. Morgan Important Disclosures:

Acorda Therapeutics Inc. (ACOR)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of Acorda Therapeutics Inc.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Acorda Therapeutics Inc.

Agios Pharmaceuticals (AGIO)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of Agios Pharmaceuticals.

Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for Agios Pharmaceuticals within the past 12 months.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Agios Pharmaceuticals.

Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: Agios Pharmaceuticals.

Client/Non-Investment Banking, Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Agios Pharmaceuticals.

Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation from investment banking Agios Pharmaceuticals.

Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Agios Pharmaceuticals.

Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Agios Pharmaceuticals.

Alexion Pharmaceuticals (ALXN)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of Alexion Pharmaceuticals.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Alexion Pharmaceuticals.

Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: Alexion Pharmaceuticals.

Client/Non-Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-securities-related: Alexion Pharmaceuticals.

Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation from investment banking Alexion Pharmaceuticals.

Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Alexion Pharmaceuticals.

Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Alexion Pharmaceuticals.

Alnylam Pharmaceuticals (ALNY)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of Alnylam Pharmaceuticals.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Alnylam Pharmaceuticals.

Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: Alnylam Pharmaceuticals.

Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation from investment banking Alnylam Pharmaceuticals.

Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Alnylam Pharmaceuticals.

Amgen Inc. (AMGN)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of Amgen Inc.

Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for Amgen Inc within the past 12 months.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Amgen Inc.

Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: Amgen Inc.

Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation from investment banking Amgen Inc.

Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Amgen Inc.

Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Amgen Inc.

Biogen Idec (BIIB)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of Biogen Idec.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Biogen Idec.

Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Biogen Idec.

Celgene (CELG)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of Celgene.

Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for Celgene within the past 12 months.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Celgene.

Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: Celgene.

Client/Non-Securities-Related: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-securities-related: Celgene.

Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation from investment banking Celgene.

Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Celgene.

Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Celgene.

ChemoCentryx, Inc. (CCXI)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of ChemoCentryx, Inc.

Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for ChemoCentryx, Inc. within the past 12 months.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: ChemoCentryx, Inc..

Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: ChemoCentryx, Inc..

Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation from investment banking ChemoCentryx, Inc..

Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from ChemoCentryx, Inc.

Dynavax (DVAX)

Important Disclosures:

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Dynavax.

Enanta Pharmaceuticals (ENTA)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of Enanta Pharmaceuticals.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Enanta Pharmaceuticals.

Gilead Sciences (GILD)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of Gilead Sciences.

Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for Gilead Sciences within the past 12 months.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Gilead Sciences.

Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: Gilead Sciences.

Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation from investment banking Gilead Sciences.

Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Gilead Sciences.

Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Gilead Sciences.

Idenix Pharmaceuticals (IDIX)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of Idenix Pharmaceuticals.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Idenix Pharmaceuticals.

InterMune (ITMN)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of InterMune.

Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for InterMune within the past 12 months.

Beneficial Ownership (1% or more): J.P. Morgan beneficially owns 1% or more of a class of common equity securities of InterMune.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: InterMune.

Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: InterMune.

Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation from investment banking InterMune.

Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from InterMune.

Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from InterMune.

Ironwood Pharmaceuticals (IRWD)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of Ironwood Pharmaceuticals.

Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for Ironwood Pharmaceuticals within the past 12 months.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Ironwood Pharmaceuticals.

Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: Ironwood Pharmaceuticals.

Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation from investment banking Ironwood Pharmaceuticals.

Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Ironwood Pharmaceuticals.

Medivation (MDVN)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of Medivation.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Medivation.

Merrimack Pharmaceuticals (MACK)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of Merrimack Pharmaceuticals.

Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for Merrimack Pharmaceuticals within the past 12 months.

Analyst Position: The following analysts (and/or their associates or household members) own a long position in the shares of Merrimack Pharmaceuticals.: Bram Kaplan.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Merrimack Pharmaceuticals.

Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: Merrimack Pharmaceuticals.

Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation from investment banking Merrimack Pharmaceuticals.

Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Merrimack Pharmaceuticals.

Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Merrimack Pharmaceuticals.

NPS Pharmaceuticals (NPSP)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of NPS Pharmaceuticals.

Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for NPS Pharmaceuticals within the past 12 months.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: NPS Pharmaceuticals.

Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: NPS Pharmaceuticals.

Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation from investment banking NPS Pharmaceuticals.

Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from NPS Pharmaceuticals.

Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from NPS Pharmaceuticals.

Ophthotech (OPHT)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of Ophthotech.

Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for Ophthotech within the past 12 months.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Ophthotech.

Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: Ophthotech.

Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation from investment banking Ophthotech.

Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Ophthotech.

Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Ophthotech.

PTC Therapeutics (PTCT)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of PTC Therapeutics.

Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for PTC Therapeutics within the past 12 months.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: PTC Therapeutics.

Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: PTC Therapeutics.

Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation from investment banking PTC Therapeutics.

Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from PTC Therapeutics.

Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from PTC Therapeutics.

Regeneron Pharmaceuticals (REGN)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of Regeneron Pharmaceuticals.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Regeneron Pharmaceuticals.

Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Regeneron Pharmaceuticals.

Synageva BioPharma (GEVA)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of Synageva BioPharma.

Lead or Co-manager: J.P. Morgan acted as lead or co-manager in a public offering of equity and/or debt securities for Synageva BioPharma within the past 12 months.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Synageva BioPharma.

Client/Investment Banking: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as investment banking clients: Synageva BioPharma.

Investment Banking (past 12 months): J.P. Morgan received in the past 12 months compensation from investment banking Synageva BioPharma.

Investment Banking (next 3 months): J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Synageva BioPharma.

Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Synageva BioPharma.

United Therapeutics (UTHR)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of United Therapeutics.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: United Therapeutics.

Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from United Therapeutics.

Vertex Pharmaceuticals (VRTX)

Important Disclosures:

Market Maker: JPMS makes a market in the stock of Vertex Pharmaceuticals.

Client: J.P. Morgan currently has, or had within the past 12 months, the following company(ies) as clients: Vertex Pharmaceuticals.